Prescription of Extended-Release Olanzapine (Zyprexa Relprevv®) requires completion of a special Risk Evaluation and Mitigation Strategies (REMS) training.
Information on this can be obtained at the manufacturer’s website at: https://www.zyprexarelprevvprogram.com/public/Default.aspx
and at the FDA’s website at:
https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=IndvRemsDetails.page&REMS=74
Related Pages
Extended-Release Olanzapine (Zyprexa Relprevv®): Basic Information
Copyright © 2017, Rajnish Mago, MD. All rights reserved. May not be reproduced in any form without express written permission.
Disclaimer: The content on this website is provided as general education for medical professionals. It is not intended or recommended for patients or other lay persons or as a substitute for medical advice, diagnosis, or treatment. Patients must always consult a qualified health care professional regarding their diagnosis and treatment. Healthcare professionals should always check this website for the most recently updated information.